GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (NAS:RYTM) » Definitions » YoY EBITDA Growth

RYTM (Rhythm Pharmaceuticals) YoY EBITDA Growth : 69.38% (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Rhythm Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Rhythm Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was 69.38%.

Rhythm Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2025 was $-0.69.

Rhythm Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Rhythm Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Pharmaceuticals YoY EBITDA Growth Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.21 54.32 -142.25 12.62 -33.62

Rhythm Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -163.40 41.85 9.78 0.97 69.38

Rhythm Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Rhythm Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-3.903--2.921)/ | -2.921 |
=-33.62 %

Rhythm Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EBITDA Growth (Q: Mar. 2025 )
=(EBITDA per Share (Q: Mar. 2025 )-EBITDA per Share (Q: Mar. 2024 )) / | EBITDA per Share (Q: Mar. 2024 )) |
=(-0.692--2.26)/ | -2.26 |
=69.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Rhythm Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (NAS:RYTM) » Definitions » YoY EBITDA Growth
Comparable Companies
PTCT PCVX RNA SLNO ZLAB RARE ACLX SWTX IONS CRSP VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
1RV:Germany 1RV:Germany
Address
222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Website
https://www.rhythmtx.com
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Executives
Pamela J. Cramer officer: Chief Human Resources Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Yann Mazabraud officer: EVP, Head of International C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
Christopher Paul German officer: Corporate Controller & CAO C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Joseph Shulman officer: Chief Technical Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Hunter C Smith officer: CFO and Treasurer C/O GENESEE & WYOMING INC., 20 WEST AVENUE, DARIEN CT 06820
Jennifer Chien officer: EVP, Head of North America C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
David P Meeker director C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Jennifer L Good director 15 GREAT RING ROAD, SANDY HOOK CT 06482
Lynn A. Tetrault director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
William T. Roberts officer: Chief Accounting Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Linda Shapiro Manning officer: Chief Medical Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Todd Foley director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Camille L Bedrosian director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nithya Desikan officer: Chief Commercial Officer 82 BAY STATE ROAD, BELMONT MA 02478